Expression of α1-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT2A receptors by Santana, Noemí et al.
Expression of a1-adrenergic receptors in rat
prefrontal cortex: cellular co-localization with
5-HT2A receptors
Noemı´ Santana1,2, Guadalupe Mengod1,3 and Francesc Artigas1,2
1 Department of Neurochemistry and Neuropharmacology, IIBB-CSIC, IDIBAPS, Barcelona, Spain
2 Centro de Investigacio´n Biome´dica en Red de Salud Mental (CIBERSAM), Madrid, Spain
3 Centro de Investigacio´n Biome´dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
Abstract
The prefrontal cortex (PFC) is involved in behavioural control and cognitive processes that are altered in
schizophrenia. The brainstemmonoaminergic systems control PFC function, yet the cells/networks involved are
not fully known. Serotonin (5-HT) and norepinephrine (NE) increase PFC neuronal activity through the acti-
vation of a1-adrenergic receptors (a1ARs) and 5-HT2A receptors (5-HT2ARs), respectively. Neurochemical and
behavioural interactions between these receptors have been reported. Further, classical and atypical anti-
psychotic drugs share nM in vitro aﬃnity for a1ARs while having preferential aﬃnity for D2 and 5-HT2ARs,
respectively. Using double in situ hybridization we examined the cellular expression of a1ARs in pyramidal
(vGluT1-positive) and GABAergic (GAD65/67-positive) neurons in rat PFC and their co-localization with 5-
HT2ARs. a1ARs are expressed by a high proportion of pyramidal (59–85%) and GABAergic (52–79%) neurons.
The expression in pyramidal neurons exhibited a dorsoventral gradient, with a lower percentage of a1AR-
positive neurons in infralimbic cortex compared to anterior cingulate and prelimbic cortex. The expression of
a1A, a1B and a1D adrenergic receptors was segregated in diﬀerent layers and subdivisions. In all them there is a
high co-expression with 5-HT2ARs (y80%). These observations indicate that NE controls the activity of most
PFC pyramidal neurons via a1ARs, either directly or indirectly, via GABAergic interneurons. Antipsychotic
drugs can thus modulate the activity of PFC via a1AR blockade. The high co-expression with 5-HT2ARs indicates
a convergence of excitatory serotonergic and noradrenergic inputs onto the same neuronal populations.
Moreover, atypical antipsychotics may exert a more powerful control of PFC function through the simultaneous
blockade of a1ARs and 5-HT2ARs.
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Introduction
The prefrontal cortex (PFC) is critically involved in many
higher brain functions, including cognition, attention
and behavioural planning (Fuster, 1997 ; Miller & Cohen,
2001). Anatomical, cellular and neurochemical alterations
of the PFC have been reported in schizophrenia (Harrison,
1999 ; Lewis&Lieberman, 2000 ; Lewis et al. 2005; Selemon
& Goldman-Rakic, 1999 ; Weinberger et al. 2001).
The brainstem monoaminergic systems innervate the
PFC and modulate the activity of memory networks
and animal behaviour (Carli et al. 2006; Dalley et al. 2004;
Ramos & Arnsten, 2007 ; Robbins, 2000; Roberts et al.
1994; Vijayraghavan et al. 2007; Winstanley et al. 2003).
Particular attention has been paid to the dopaminergic
system, which ﬁnely tunes the activity of PFC neurons
during spatial workingmemory tasks via D1 receptors in a
bell-shaped manner (Vijayraghavan et al. 2007; Williams
& Goldman-Rakic, 1995).
Less is known of the role of norepinephrine (NE)
and serotonin (5-HT) in PFC function. Hence, moderately
elevated levels of NE acting on a2A-adrenergic receptors
(a2AARs) improve cognitive performance whereas high
NE release (e.g. as evoked by stress) impairs cognitive
performance by activating a1ARs (Ramos & Arnsten,
2007). On the other hand, 5-HT2AR blockade partly
antagonizes the neuronal activation during a spatial
working-memory task (Williams et al. 2002) and sero-
tonin (5-HT) depletion in monkey orbitofrontal cortex
impaired reversal learning (Clarke et al. 2004). Further, the
local blockade of PFC 5-HT2ARs improves visuospatial
attention and decreases impulsivity in rats (Winstanley
et al. 2003).
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Electrophysiological studies in rodents have
shown that NE and 5-HT can modulate the activity of
PFC neurons in vivo and in vitro (Aghajanian &
Marek, 1997 ; Araneda & Andrade, 1991 ; Arvanov et al.
1999; Ashby et al. 1989; Fe´re´zou et al. 2002; McCormick
et al. 1993; Puig et al. 2003, 2004, 2005; Tanaka &
North, 1993 ; Zhang & Arsenault, 2005; Zhou & Hablitz,
1999). In particular, the excitatory actions of NE and 5-HT
on PFC cells may be involved in the maintenance of
activity patterns during working-memory tasks. These
excitatory actions are mediated by a1ARs and 5-HT2ARs,
respectively (Aghajanian & Marek, 1997 ; Araneda &
Andrade, 1991 ; Puig et al. 2003, 2005 ; Zhang & Arsenault,
2005). Additionally, 5-HT can excite GABAergic inter-
neurons via 5-HT3 receptors (Gui et al. 2010; Puig et al.
2004).
The knowledge of the cellular and network basis of
NE and 5-HT modulation of PFC activity is also import-
ant in clarifying the mechanism of action of antipsychotic
drugs. Hence, classical antipsychotics show high aﬃnity
for D2 receptors, whereas atypical antipsychotics
show preferential aﬃnity for 5-HT2ARs vs. D2 receptors.
Yet, all of them share high aﬃnity for a1ARs (Arnt &
Skarsfeldt, 1998 ; Bymaster et al. 1996; Meltzer, 1999)
although the potential therapeutic role of a1AR blockade
has been obscured by its involvement in cardiovascular
side-eﬀects.
Interestingly, functional interactions between 5-HT2A
and a1ARs have been reported, which may be involved in
the therapeutic activity of antipsychotic drugs. Hence,
neurochemical and behavioural actions of 5-HT2AR
agonists can be antagonized by 5-HT2AR and a1AR
blockade as well as by antipsychotic drugs (Amargo´s-
Bosch et al. 2003; Bortolozzi et al. 2003; Dursun &
Handley, 1996; Schreiber et al. 1995). Conversely, neuro-
chemical eﬀects of the a1AR agonist cirazoline in PFC can
be reversed by prazosin, M100907 (a selective 5-HT2AR
antagonist) and by antipsychotic drugs (Amargo´s-Bosch
et al. 2003). 5-HT2A/a1AR interactions may also partici-
pate in the action of opiates and psychostimulants
(Auclair et al. 2004).
The cellular/network basis of the above interactions
is unknown. Previous studies have revealed the presence
of 5-HT2ARs in pyramidal and GABAergic neurons of
rat PFC (Martı´n-Ruiz et al. 2001; Santana et al. 2004).
However, the cellular expression of a1AR is presently
unknown. Using double in situ hybridization, we per-
formed a quantitative study on the expression of a1A, a1B
and a1D adrenergic receptors in pyramidal vesicular glu-
tamate transporter 1 (vGluT1)-positive) and GABAergic
(GAD65/67-positive) cells of rat PFC. Similarly, given the
common signalling pathways shared by 5-HT2A and
a1ARs (Gq/11 G proteins) (Bartrup & Newberry, 1994;
Berg et al. 1998; Claro et al. 1993; Michel et al. 1993;
Molinoﬀ, 1984) and the above functional interactions, we
examined the co-expression of both receptors in rat PFC
using double in situ hybridization.
Materials and method
Tissue preparation
Male albino Wistar rats weighing 250–300 g (Iﬀa
Credo, France) were used. Animals were kept in a con-
trolled environment [12-h light–dark cycle (lights on
08:00 hours) and 22¡2 xC room temperature] with food
and water provided ad libitum. Animal care followed
the European Union regulations (OJ of EC L358/1 18/12/
1986) and was approved by the local Institutional Animal
Care and Use Committee. Rats were killed by decapi-
tation and the brains rapidly removed, frozen on dry ice
and stored atx20 xC. Tissue sections, 14-mm thick, were
cut using a microtome-cryostat (HM500 OM; Microm,
Germany), thaw-mounted onto 3-aminopropyltriethoxy-
silane- (APTS; Sigma, USA) coated slides and kept at
–20 xC until use.
Hybridization probes
The oligodeoxyribonucleotide probes used were comp-
lementary to the following bases : 2–46 and 1395–1439
of the rat a1AAR mRNA (GenBank accession no.
NM_017191.1) ; 365–409 and 2216–2260 of the rat a1BAR
mRNA (GenBank accession no. X51585.1) ; 1167–1212
of the rat a1DAR mRNA (GenBank accession no.
NM_024483.1) ; 128–170, 180–224, 836–880, 939–987,
1301–1345 and 1380–1427 of the rat 5-HT2AR mRNA
(GenBank accession no. NM_017254.1), 514–558 of
the isoform of the enzyme glutamate decarboxylase
(GAD65) mRNA (GenBank accession no. NM_012563.1) ;
1600–1653 of the GAD67 mRNA (GenBank accession no.
NM_017007.1) ; 127–171 and 1756–1800 of the vGluT1
mRNA (GenBank accession no. NM_053859.1).
All probes were synthesized and HPLC puriﬁed
by Isogen Bioscience BV (Maarsden, The Netherlands)
and labelled either with 33P or with digoxigenin (Dig).
Each receptor oligonucleotide was individually labelled
(2 pmol) at the 3k-end either with [33P]dATP (>2500 Ci/
mmol ; DuPont-NEN, USA) using terminal deoxy-
nucleotidyltransferase (TdT, Calbiochem, USA). GAD
and vGluT oligonucleotides (100 pmol) were non-
radioactively labelled with TdT (Roche Diagnostics
GmbH, Germany) and Dig-11-dUTP (Boehringer
Mannheim). Oligonucleotides were puriﬁed by cen-
trifugation using ProbeQuantTM G-50 micro columns
(GE Healthcare UK Ltd, UK). All probes were tested for
speciﬁcity prior to use.
In situ hybridization histochemistry procedure
The protocol for single- and double-label in situ hy-
bridization has been published elsewhere (Serrats et al.
2003). Frozen tissue sections were ﬁrst brought to
room temperature, ﬁxed for 20 min at 4 xC in 4% para-
formaldehyde in phosphate-buﬀered saline (1rPBS:
8 mM Na2HPO4, 1.4 mM KH2PO4, 136 mM NaCl, 2.6 mM
KCl), washed for 5 min in 3rPBS at room temperature,
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twice for 5 min each in 1rPBS and incubated for 2 min at
21 xC in a solution of predigested pronase (Calbiochem,
USA) at a ﬁnal concentration of 24 U/ml in 50 mM
Tris–HCl (pH 7.5), 5 mM EDTA. The enzymatic activity
was stopped by immersion for 30 s in 2 mg/ml glycine
in 1rPBS. Tissues were ﬁnally rinsed in 1rPBS and
dehydrated through a graded series of ethanol. For
hybridization, the radioactively labelled and the non-
radioactively labelled probes were diluted in a solution
containing 50% formamide, 4rSSC (1rSSC: 150 mM
NaCl, 15 mM sodium citrate), 1rDenhardt’s solution
(0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA),
10% dextran sulfate, 1% sarkosyl, 20 mM phosphate
buﬀer (pH 7.0), 250 mg/ml yeast tRNA and 500 mg/ml
salmon sperm DNA. The ﬁnal concentrations of radioac-
tive and Dig-labelled probes in the hybridization buﬀer
were in the same range (y1.5 nM). Tissue sections were
covered with hybridization solution containing the
labelled probe(s), overlaid with Nescoﬁlm coverslips
(Bando Chemical Indistries, Japan) and incubated over-
night at 42 xC in humidity boxes. Sections were then
washed four times (45 min each) in a buﬀer containing
0.6 M NaCl and 10 mM Tris–HCl (pH 7.5) at 60 xC.
Development of radioactive and non-radioactive
hybridization signal
Hybridized sections were treated as described by Landry
et al. (2000) (see updated procedures in Santana et al. 2004,
2009). Brieﬂy, after washing, the slides were immersed
for 30 min in a buﬀer containing 0.1 M Tris–HCl (pH 7.5),
1 M NaCl, 2 mM MgCl2 and 0.5% BSA (Sigma) and
incubated overnight at 4 xC in the same solution with
alkaline-phosphate-conjugated anti-digoxigenin-F(ab)
fragments (1 :5000 ; Boehringer Mannheim, Germany).
Afterwards, they were washed three times (10 min each)
in the same buﬀer (without antibody) and twice in an
alkaline buﬀer containing 0.1 M Tris–HCl (pH 9.5), 0.1 M
NaCl and 5 mM MgCl2. Alkaline phosphatase activity
was developed by incubating the sections with 3.3 mg
nitroblue tetrazolium and 3.3 mg bromochloroindolyl
phosphate (Gibco BRL, USA) diluted in 10 ml alkaline
buﬀer. The enzymatic reaction was blocked by extensive
rinsing in the alkaline buﬀer containing 1 mM EDTA. The
sections were then brieﬂy dipped in 70% and 100%
ethanol, air-dried and dipped into Ilford K5 nuclear
emulsion (Ilford, UK) diluted 1:1 with distilled water.
They were exposed in the dark at 4 xC for 5 wk and
ﬁnally developed in Kodak D19 (Kodak, USA) for 5 min
and ﬁxed in Ilford Hypam ﬁxer (Ilford).
Analysis of the results
Tissue sections were examined in bright- and dark-ﬁeld
in a Wild 420 macroscope (Leica, Germany) and in a
Nikon Eclipse E1000 microscope (Nikon, Japan) equip-
ped with bright- and dark-ﬁeld condensers for trans-
mitted light and with epi-illumination. Micrography was
performed using a digital camera (DXM1200 3.0 ; Nikon)
and analySIS software (Soft Imaging System GmbH,
Germany). Bright-ﬁeld images were captured with
transmitted light. Dark-ﬁeld images were captured with
Darklite illuminator (Micro Video Instruments, USA).
The ﬁgures were prepared for publication using Adobe
Photoshop software (Adobe Software, USA). The cellular
counting was performed with an Olympus AX70 stereo
microscope using CAST software for stereological analy-
sis, and an Olympus BX51 stereo microscope equipped
with an Olympus microscope digital camera DP71 and
Visiopharm Integrator System software (Olympus). Data
for total a1AR expression was obtained by hybridizing
PFC sections with a combination of the oligonucleotides
selective for a1A, a1B and a1D adrenergic receptor mRNA.
Co-expression data of vGluT1, GAD, or 5-HT2AR-positive
cells (Dig-labelled cells) with a1AR mRNA (or individual
a1A, a1D and a1D adrenergic receptor mRNA) was esti-
mated by counting the number of Dig-labelled cellular
proﬁles which also expressed a1ARmRNA (radioactively
labelled cells). Relative proportions were estimated by
considering 100% of the Dig-labelled cells. Only cellular
proﬁles showing 2-fold density of silver grains from
background were considered to be double-labelled. Data
are means¡S.E.M. of three rats (duplicate/triplicate sec-
tions per rat, see Figure legends).
Results
Expression of a1AR in the rat PFC
The various subtypes of a1AR mRNA were abundantly
expressed in rat PFC, in particular a1A and a1D adrenergic
receptors. Figure 1 shows the distribution of each indi-
vidual a1AR transcript. Several features can be re-
cognized. First, virtually all subdivisions of the PFC
contained cells expressing one or more a1ARs. Second,
most abundant transcripts were those corresponding to
a1A and a1D adrenergic receptors, whereas the expression
of a1BAR was more moderate, particularly in the medial
PFC (mPFC). Third, with few exceptions, the various
a1AR transcripts showed an almost non-overlapping
regional distribution within the mPFC. This was par-
ticularly remarkable for a1A and a1D adrenergic receptors.
The former transcript was densely expressed in deep
layers (VIa, VIb) of the medial, dorsal and lateral (agra-
nular insular) PFC and the claustrum as well as in
ventral areas, such as orbital and piriform cortices and
the tenia tecta (TT). In contrast, the a1DAR transcript was
particularly abundant in intermediate layers (layers II–III,
outer layer V) in medial and dorsolateral aspects of
the PFC as well as in orbital cortex and had a much
more restricted expression in TT and piriform cortex.
In addition to this diﬀerential regional distribution
(see Fig. 1a, c), there was a common expression of both
receptors in superﬁcial layers of medial and dorsolateral
aspects of the PFC.
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The density of the a1BAR transcript was lower than
that of a1AARs and a1DARs. Moreover, its regional dis-
tribution was more restricted, being localized to dorsal
and lateral aspects of PFC (layers III–V), as well as orbital
and piriform cortices.
Expression of a1ARs in pyramidal and GABAergic
neurons of the rat PFC
In double in situ hybridization experiments, we observed
the presence of all three types of a1ARs in pyramidal
(vGluT1-positive) and GABAergic (GAD65/67-positive)
neurons. Figures 2–4 show representative examples of
the presence of a1A, a1B and a1D adrenergic receptor trans-
cripts in pyramidal and GABAergic neurons in various
layers of themPFC. Note the abundance of pyramidal and
GABAergic neurons expressing a1A and a1D adrenergic
receptors. Table 1 shows the proportion of pyramidal
and GABAergic neurons in the cingulate, prelimbic and
infralimbic areas of the mPFC expressing a1ARs.
The proportion of pyramidal neurons expressing
a1ARs in the diﬀerent cortical layers and areas of the
mPFC was very high (59–85%), being maximal in layers
II–III and V of the cingulate and prelimbic areas (71–85%)
(Table 1). There was a dorsoventral gradient in the
proportion of pyramidal cells expressing a1ARs, with a
greater percentage in the anterior cingulate and a lower
proportion in the infralimbic area, particularly in layer VI
(Table 1).
Similarly, a very high proportion of GABAergic
neurons also expressed a1ARs (52–79%). GABAergic cells
expressing each of the three a1AR subtypes were found in
diﬀerent cortical layers, including layer I. Figures 2–4
show representative examples of GABAergic cells ex-
pressing a1A, a1B and a1D adrenergic receptors in the
mPFC. Interestingly, unlike the other a1AR subtypes,
some cells in superﬁcial layers of the prelimbic area ex-
hibited a remarkably high level of the a1BAR transcript
(data not shown).
Further analysis of the regional expression of the dif-
ferent a1AR subtypes revealed that pyramidal neurons
expressing a1AARs were more abundantly localized in
deep layers (V–VI) in the three mPFC subdivisions
(ACAd, PL, ILA) (layer factor : F1,12=35.7, p<0.0001 ; re-
gion factor : n.s. ; two-way ANOVA). No eﬀect of layer
and region was found for a1AARs expressed in
GABAergic neurons. In contrast, pyramidal neurons ex-
pressing a1DARs were mainly localized in superﬁcial
layers (II–III) in the same regions (layer factor : F1,12=
453.7, p<0.0001; region factor : F1,12=6.7, p<0.05 ;
(a)
MOs
ACAd
layer VI
ORB
PL
ILA AI
TT
PIR
(b) (c)
Fig. 1. Lowmagniﬁcation dark-ﬁeld photomicrographs showing the localization of (a) a1A, (b) a1B, and (c) a1D adrenergic receptor (AR)
mRNA in the rat prefrontal cortex using in situ hybridization histochemistry. The sections correspond approximately to AP+3.7 mm
(Paxinos &Watson, 2005). Each receptor transcript was detected with 33P-labelled oligonucleotides. (a) a1AARmRNAwas localized to a
large number of cells in superﬁcial, middle and, particularly, deep layers of the various areas of the medial prefrontal cortex (mPFC),
such as the anterior cingulate (ACAd), prelimbic (PL) and infralimbic (ILA) areas. It was also present in dorsal and lateral aspects of the
PFC, such as the motor area (MO) and the agranular insular (AI) cortex as well as in ventral prefrontal areas (orbital cortex, ORB;
piriform cortex, PIR ; tenia tecta, TT) (nomenclature from Swanson, 2005). (b) The localization of a1BARmRNAwas mainly restricted to
intermediate layers (layer III, upper layer V) in dorsolateral aspects of the PFC and in ventral orbital cortex. A moderate number of
cells, in the cingulate and prelimbic areas of the mPFC as well as in the piriform cortex, also expressed a1BARmRNA. (c) a1DARmRNA
was also abundant, yet with a diﬀerent, and almost complementary distribution than that of a1AARmRNA. It was expressed by a large
number of cells in superﬁcial layer V and in layers II–III. The various areas of mPFC, including the infralimbic area, contained a large
number of cells expressing a1DAR mRNA in intermediate layers. However, unlike a1AAR mRNA, it was expressed by a reduced
number of cells in layer VI and in ventral aspects of the PFC. Bar size, 1 mm.
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A1 A2 A3
B1 B2 B3
Fig. 2. Top row (A1–A3). High magniﬁcation photomicrographs showing the presence of a1A adrenergic receptor mRNA (detected by
hybridization with 33P-labelled oligonucleotides, seen as silver grains) in layer V pyramidal cells of the prelimbic area. Pyramidal
neurons were identiﬁed by the presence of vesicular glutamate transporter 1 mRNA (detected by hybridization with Dig-labelled
oligonucleotides, seen as dark precipitates). Red arrowheads indicate cells positive for both transcripts. For the sake of simplicity, only
few cells of each type are shown. The majority of glutamatergic cells expressed a1A adrenergic receptor mRNA, as denoted by the
double labelling. Bottom row (B1–B3). a1A adrenergic receptor mRNA was also found in GABAergic (GAD65/67-positive) cells
throughout the prefrontal cortex (Dig-labelled oligonucleotides, dark precipitates). Panels B1 and B2 show the presence of a1A
adrenergic receptor mRNA in some GABAergic cells of layer I and deep layers, of the prelimbic area, respectively, in the medial
prefrontal cortex. Panel B3 shows double-labelled cells in the prelimbic area at higher magniﬁcation. Bar size, 20 mm.
A1 A2 A3
B1 B2 B3
Fig. 3. Top row (A1–A3). High magniﬁcation photomicrographs showing the presence of a1B adrenergic receptor (AR) mRNA
(33P-labelled oligonucleotides, silver grains) in pyramidal cells, identiﬁed by the presence of vesicular glutamate transporter 1 mRNA
(Dig-labelled oligonucleotides, dark precipitates). Panel A1 corresponds to layers II–III of anterior cingulate area. Panel A2 shows
double-labelled cells in intermediate layers (III–V) of prelimbic cortex. Panel A3 shows a higher magniﬁcation of individual cells
expressing both transcripts in the same area. Bottom row (B1–B3). a1BAR mRNA was also found in GABAergic cells. Panels B1 and B2
show the presence of a1BARmRNA in some GABAergic cells of layers I and II–III, respectively, of the prelimbic cortex. Panel B3 shows
a double-labelled cell in layers II–III of prelimbic cortex at a higher magniﬁcation. Red arrowheads indicate double-labelled cells. Blue
arrowheads indicate cells only positive for a1BAR mRNA. Bar size, 20 mm.
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two-way ANOVA) (Fig. 5). GABAergic neurons express-
ing a1DAR were also localized in superﬁcial layers (layer
factor : F1,12=53.3, p<0.0001; region factor : F1,12=8.6,
p<0.05 ; two-way ANOVA) (Fig. 5).
Co-expression of a1ARs and 5-HT2ARs in rat PFC
The regional distribution of a1AR and 5-HT2AR mRNA
was very similar in PFC (Fig. 6). Figure 6b corresponds to
the combined expression of all three a1AR subtypes,
obtained by hybridizing PFC sections with a combination
of the oligonucleotides selective for a1A, a1B and a1D
adrenergic receptor mRNA, as described in the Method
section.
With the exception of layer VI, and the more ventral
part of the infralimbic cortex, with low 5-HT2AR mRNA
expression, virtually all other areas in PFC showed an
abundant expression of both receptor transcripts. These
areas included the cingulate and prelimbic areas of the
mPFC, motor, agranular insular, orbital and piriform
cortices, and TT. (See Fig. 1 for a detailed comparison of
the expression of 5-HT2ARs with each one of the three
a1AR subtypes.)
Double in situ hybridization experiments were con-
ducted to examine the possible cellular co-localization
of 5-HT2AR with a1A, a1B and a1D adrenergic receptors, as
well as with the three subtypes together (total a1 AR).
Figures 6 and 7 show the extensive cellular co-expression
of 5-HT2ARs with a1ARs, especially with a1AAR, and
a1DAR subtypes, in various ﬁelds of the mPFC as well as
in other PFC areas such as piriform cortex, TT or agra-
nular insular cortex. We performed a detailed estimation
of the percentage of cellular co-expression of 5-HT2ARs
with a1ARs in layers II–III of the mPFC (cingulate, pre-
limbic, infralimbic areas) (Fig. 8). Given the limited ex-
pression and restricted localization of a1BARs, we did
not carry out the cellular counting of this receptor sub-
type. Taking 5-HT2A-expressing cells as 100%, the
A1 A2 A3
B1 B2 B3
Fig. 4. Top row (A1–A3). High magniﬁcation photomicrographs showing the presence of a1D adrenergic receptor (AR) mRNA
(33P-labelled oligonucleotides, silver grains) in pyramidal cells, identiﬁed by the presence of vesicular glutamate transporter 1 mRNA
(Dig-labelled oligonucleotides, dark precipitates) of layers II–III of prelimbic cortex. Red arrowheads indicate cells positive for both
transcripts. For the sake of simplicity, only few cells of each type are shown. Note that the majority of glutamatergic cells expressed
a1DAR mRNA. Bottom row (B1–B3). The a1D AR mRNA was also found in GABAergic cells. Panel B1 shows the presence of a1DAR
transcript in a GABAergic cell of prelimbic layer I. Panel B2 shows layers II–III of prelimbic cortex. Panel B3 shows a higher
magniﬁcation of a double-labelled cell in layers II–III of prelimbic cortex. Bar size, 20 mm.
Table 1. Expression of a1 adrenergic receptors in pyramidal
(vGluT1-positive) and GABAergic (GAD65/67-positive) neurons
of the rat mPFC
Area Layers II–III Layer V Layer VI
vGluT1-positive ACAd 85¡4* 71¡9 65¡8
PL 80¡3* 79¡8* 59¡2
ILA 62¡8 63¡8
GAD-positive ACAd 79¡10 73¡14 62¡1
PL 79¡5* 72¡5 57¡8
ILA 74¡3 52¡6**
vGluT1, Vesicular glutamate transporter 1 ; GAD, glutamate
decarboxylase ; PFC, prefrontal cortex.
Data (mean¡S.E.M.) are percentages of pyramidal or GABAergic
neurons expressing total a1ARs in the various cortical layers
of the dorsal anterior cingulate (ACAd), prelimbic (PL) and
infralimbic (ILA) areas of the rat mPFC. * p<0.05 vs. layer VI,
** p<0.05 vs. layers I–III, Tukey’s test post-ANOVA. Data are
means¡S.E.M. of three rats (triplicate sections per rat).
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Fig. 5. Bar graph showing the percentage of pyramidal (vesicular glutamate transporter 1-positive) and GABAergic (GAD-positive)
neurons expressing each a1-adrenergic receptor subtype in superﬁcial (II–III) and deep (V–VI) layers of infralimbic (ILA),
prelimbic (PL) and cingulate (ACAd) subdivisions of medial prefrontal cortex. * p<0.05 vs. deep layers of the same area,
Newman–Keuls test post-ANOVA. Data are means¡S.E.M. of three rats (duplicate sections per rat).
(a) (b)
Fig. 6. Low magniﬁcation dark-ﬁeld photomicrographs showing the localization of (a) 5-HT2AR mRNA, and (b) a1 adrenergic
receptor mRNA in rat prefrontal cortex (PFC) using in situ hybridization histochemistry. The sections correspond approximately to
AP+3.7 mm (Paxinos & Watson, 2005). Each receptor transcript was labelled with 33P-labelled oligonucleotides. (a) As previously
described (Amargo´s-Bosch et al. 2004 ; Santana et al. 2004), cells expressing 5-HT2ARs are located in most dorsal and ventral PFC
regions, yet a low density of expressing cells was found in the infralimbic area and layer VIa of the mPFC. Note the presence of
cells containing the 5-HT2AR transcript in various cortical layers. This was particularly evident in dorsal and lateral aspects of PFC.
(b) Cells expressing one or more type of a1ARs were still more abundant than those expressing 5-HT2ARs. Virtually all areas of the
PFC showed the presence of a1A, a1B, and a1D adrenergic receptor mRNA. Open squares indicate the approximate location of areas
where co-expression of both receptors was examined (Fig. 6). Bar size, 1 mm.
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Fig. 7. Co-localization of 5-HT2A mRNA (Dig-labelled oligonucleotides, dark precipitates) with the diﬀerent types of a1
adrenergic receptor (AR) mRNA (33P-labelled oligonucleotides, silver grains) in various areas of the rat prefrontal cortex (PFC).
(A1–A3) Co-localization with a1AARs in the prelimbic cortex ; Panels A1 and A3 show, at diﬀerent magniﬁcation, cells expressing
both receptors mRNA in layers II–III whereas panel A2 shows some cells in layer VI. Note the presence of cells positive for a1AARs
and negative for 5-HT2ARs (blue arrowheads), as expected from the scarcity of cells expressing 5-HT2ARs and abundance of a1AARs
in deep layers. (B1–B3) Co-localization of 5-HT2ARs with a1BARs in layers II–III of the anterior cingulate (B1 and B3) and prelimbic
(B2) cortices. As expected from the negative dorsoventral gradient of expression of a1BARs in the mPFC, there was a greater
co-expression in cingulate cortex. (C1–C3) Co-localization of 5-HT2ARs with a1DARs in layers II–III of the anterior cingulate
(C1 and C3) and layer VIb of the prelimbic cortex (C2). Note the absence of the a1DAR transcript in deep layers, and consequently,
the low level of co-expression with 5-HT2ARs. (D1–D3) Co-localization of 5-HT2AR mRNA with a1A, a1B, and a1D adrenergic receptor
mRNA (multiple probes). Panels D1 and D3 correspond to layers II–III and panel D2 corresponds to layer VI, all in prelimbic
cortex. Regarding individual a1AR mRNA, note the low co-expression in layer VI due to the small number of 5-HT2A-positive cells
in this area. Several cells positive for one or more a1AR mRNA (e.g. the a1A subtype) and negative for 5-HT2AR mRNA are
indicated with blue arrowheads. Panels E1–E3 show the high co-expression of both receptors in areas other than the mPFC.
Panel E1 shows the co-localization of the 5-HT2AR mRNA with a1AAR mRNA in tenia tecta. Panels E2 and E3 show, respectively,
the co-localization of 5-HT2AR mRNA with a1AR mRNA (multiple probes) in the piriform cortex and the ventral part of the
agranular insular cortex. Bar size, 20 mm.
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percentage of cells also expressing a1ARs varied between
44% in the infralimbic area to 75% and 80%, respectively,
in the prelimbic and cingulate areas. Given the preferen-
tial expression of a1DARs in superﬁcial layers, where cell
counts were performed, this subtype was probably the
one contributing most to co-expression with 5-HT2ARs.
However, it is likely that similar counts performed in
areas showing abundant expression of 5-HT2ARs and
a1AARs, such as the motor area or the agranular insular
cortex, would also give very high levels of co-expression,
as shown in Fig. 6.
Discussion
The present study shows that a1AR mRNA is expressed
in rat PFC in a very high proportion of pyramidal
neurons and local GABAergic interneurons. The three
a1AR subtypes show a complementary and almost
non-overlapping distribution in the diﬀerent PFC sub-
divisions and layers, which suggests speciﬁc roles for
each a1AR in the various PFC functions. Interestingly,
cells expressing a1AARs were signiﬁcantly more abun-
dant in deep layers whereas cells expressing a1DARs
were much more abundant in superﬁcial layers,
suggesting that the former receptors are involved in the
control of subcortical structures. Each a1AR type was
extensively co-expressed with 5-HT2ARs, which indicates
a convergence of excitatory noradrenergic and sero-
tonergic signals in the same PFC neurons.
To our knowledge, this is the ﬁrst study examining
the cellular localization of a1AR mRNA in mammalian
PFC. It adds to similar studies on 5-HT and dopamine
receptors relevant for antipsychotic drug action
(Amargo´s-Bosch et al. 2004; Puig et al. 2004; Santana et al.
2004, 2009). The three a1AR types occur in various cortical
areas (Day et al. 1997; Palacios et al. 1987; Pieribone et al.
1994). When examined in a study by Pieribone et al.
(1994), their regional distribution coincides essentially
with the present observations. The use of double in situ
hybridization enabled us to quantify the proportion of
pyramidal and GABAergic neurons expressing each
a1AR type. Interestingly, the proportion of each neuronal
type expressing one or more types of a1AR was surpris-
ingly high (80–86%), compared to 5-HT1A, 5-HT2A, 5-HT3,
5-HT4 or dopamine D1 and D2 receptors in rat PFC using
the same methodology (maximum of 66% for 5-HT2ARs
in ACAd) (Puig et al. 2004; Santana et al. 2004, 2009;
T. Vilaro´, personal communication).
The diﬀerence between the proportion of PFC
GABAergic interneurons expressing a1ARs or other
monoaminergic receptors is even more marked. Hence,
a maximal proportion of 32–34% GABAergic neurons
in ACAd/PL express 5–HT2ARs (Santana et al. 2004).
Moreover, 5-HT3Rs, which are exclusively expressed by
GABAergic interneurons in PFC and hippocampus
(Morales et al. 1996; Puig et al. 2004) are present in 6–40%
of GABAergic neurons in diﬀerent cortical layers (Puig
et al. 2004). Similarly, dopamine D1 and D2 receptor
mRNA is present in 5–38% of GABAergic neurons in
various PFC subdivisions (Santana et al. 2009). However,
the diﬀerent a1ARs were expressed in a much higher
proportion of GABAergic interneurons, similar to that in
pyramidal neurons (69–74% in superﬁcial layers ;
52–73% in deep layers). Overall, the presence of a1ARs in
such a large proportion of pyramidal and GABAergic
neurons suggests that NE can modulate the activity of
most PFC output neurons via direct or indirect actions, a
view consistent with electrophysiological observations,
some of which are common with those of 5-HT2AR acti-
vation (Araneda & Andrade, 1991 ; Marek & Aghajanian,
1999). Moreover, the presence of 5-HT2ARs and a1ARs in
GABAergic interneurons indicates that 5-HT and NE
may play a prominent role in the control of local PFC
networks, as observed in electrophysiological experi-
ments. Hence, both NE and 5-HT can inhibit the activity
of layer V pyramidal cells via activation of 5-HT2ARs and
a1ARs in fast-spiking GABAergic cells (Kawaguchi &
Shindou, 1998 ; Puig et al. 2010; Weber & Andrade, 2010;
Zhong & Yan, 2011).
The NE-evoked excitations of pyramidal neurons in-
volve post-synaptic a1ARs. However, there have been
controversial views on the localization of 5-HT2ARs in
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Fig. 8. Bar graphs showing the proportion of 5-HT2AR-positive cells which also express the transcripts for all a1 adrenergic receptors
(a) and for the a1A (b) and a1D (c) types in layers II–III of the various areas of the medial prefrontal cortex (ACAd, dorsal anterior
cingulate ; PL, prelimbic ; ILA, infralimbic). Data are means¡S.E.M. of three rats (duplicate sections per rat). Absolute number of
5-HT2AR-positive cells in these sections : 41¡1 (ACAd), 41¡2 (PL), and 12¡2 (ILA) cells per microscopic ﬁeld.
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PFC. Hence, while some studies suggested a presynaptic
localization on thalamocortical aﬀerents (Aghajanian
& Marek, 1997, 1999), subsequent studies did not
support this view (Beique et al. 2007; Miner et al. 2003;
Puig et al. 2003), indicating a predominant post-synaptic
localization of 5-HT2ARs in PFC neurons, in common
with a1ARs. A recent paper showed the presence of a1AR
immunoreactivity in vGluT1-positive glutamatergic
axons in PFC (Mitrano et al. 2012). This observation
would be consistent with the presence of a large pro-
portion of layer III neurons expressing a1AR transcripts
(present study), suggesting that NE may also modulate
intracortical connectivity through presynaptic excitatory
a1ARs.
The markedly high co-expression of 5-HT2AR mRNA
with that of a1ARs suggests a convergence of excitatory
signals evoked by 5-HT and NE on PFC neurons. Given
the diﬀerent proportion of GABA cells expressing
5–HT2ARs and a1ARs, it is likely that most of the co-
expression takes place in pyramidal neurons. Indeed,
immunohistochemical studies have shown that a1ARs
and 5-HT2ARs are localized in cell bodies and apical
dendrites of pyramidal neurons (Acosta-Martinez et al.
1999; Cornea-Hebert et al. 1999; Jakab & Goldman-Rakic,
1998, 2000 ; Martin-Ruiz et al. 2001). Further, functional
interactions have been reported between 5-HT2ARs and
a1ARs in the rat (see Introduction). These observations,
together with the common signalling pathways and
their functional interactions, suggest a close association
between both receptors. Whether this involves the
formation of stable heteromers, as observed with
other neurotransmitter receptors, remains to be estab-
lished. Preliminary data indicate that 5-HT2ARs co-
immunoprecipitate and show stable ﬂuorescence
resonance energy transfer (FRET) signals with all three
a1ARs expressed in HEK-293T cells (Santana et al. un-
published observations). However, this is just a ﬁrst
step in establishing the formation of receptor heteromers
in vivo (Ferre´ et al. 2009).
The present observations may have important physio-
logical and therapeutic implications. On the one hand,
PFC neuronal activity may be concurrently regulated
by the ascending 5-HT and noradrenergic systems. Since
both neuronal groups are REM-oﬀ (Aston-Jones et al.
1991; Jacobs & Azmitia, 1992) the concurrent activation
(or its lack) of excitatory a1ARs and 5-HT2ARs in the
same cells may have a synergistic eﬀect on the activity
of cortical neurons during wakefulness and sleep.
Moreover, both receptors have been involved in working
memory through the modulation of neuronal activity in
dorsolateral PFC (Ramos & Arnsten, 2007 ; Williams et al.
2002). On the other hand, dual reuptake inhibitors
(Artigas, 1995) show an antidepressant eﬃcacy higher
than selective 5-HT reuptake inhibitors, an eﬀect which
may occur via summation of eﬀects on the same cortical
neurons. Finally, conventional and second-generation
(atypical) antipsychotics share the ability to antagonize
a1ARs while the latter drugs also antagonize 5-HT2ARs
(Arnt & Skarsfeldt, 1998 ; Bymaster et al. 1996). The
therapeutic potential of a1AR blockade in schizophrenia
has been neglected due to its cardiovascular eﬀects, de-
spite the fact that prazosin enhanced the antipsychotic
actions of dopamine D2 receptor blockade (Wadenberg
et al. 2000). The present observations support the view
that a1AR and 5-HT2AR blockade may add to each other
to modulate PFC function making the PFC a particularly
sensitive area to the action of atypical antipsychotic drugs
(Artigas, 2010).
In summary, the present study shows that the ascend-
ing 5-HT and NE systems share common actions in
the PFC through the concurrent expression of a1ARs
and 5-HT2ARs in most PFC neurons, an observation
with potential physiological and pharmacological conse-
quences.
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